Efficacy of Intravenous Infusion of Acetaminophen for Intrapartum Analgesia.

J Clin Diagn Res

Senior Resident, Department of Obstetrics and Gynaecology, Vardhaman Mahavir Medical College and Safdarjung Hospital, New Delhi, India .

Published: August 2016

AI Article Synopsis

  • The study investigates the effectiveness of intravenous acetaminophen (1000 mg) as a non-opioid pain reliever for women in labor, addressing the issues related to traditional opioid use.
  • Conducted at Vardhaman Mahavir Medical College & Safdarjung Hospital, the research involved 200 pregnant women who were randomly assigned to receive either acetaminophen or a placebo (normal saline) during labor and assessed their pain levels.
  • Results indicated a significant reduction in pain intensity within the acetaminophen group compared to the placebo, with no adverse effects on mothers or babies, suggesting that intravenous acetaminophen is a safe and effective alternative for labor pain relief.

Article Abstract

Introduction: The intensity of pain experienced by women in labour, has been found to affect the progress of labour, foetal well-being and maternal psychology. Adverse effects associated with commonly used opioids for providing intrapartum analgesia have created a need for an alternative non-opioid drug.

Aim: To evaluate the efficacy of an intravenous infusion of 1000 mg of acetaminophen as an intrapartum analgesic.

Materials And Methods: The present prospective single-centre, single blind, placebo-controlled randomized interventional study was conducted in Department of Obstetrics and Gynaecology in Vardhaman Mahavir Medical College & Safdarjung Hospital over a period of six months from September 2014 to March 2015. After receiving the ethical clearance and written informed consent. The first 200 consecutive parturients fulfilling the inclusion criteria were recruited into the study. Women were then randomised to receive either intravenous 1000 mg (100ml) of acetaminophen (Group A, n=100) or 100 ml normal saline (Group B, n=100). Primary outcome assessed was effectiveness of acetaminophen to provide an adequate amount of analgesia, as measured by a change in Visual Analogue Scale (VAS) pain intensity score at various times after drug administration. Secondary outcomes measured were duration of labour, need for additional rescue analgesia and presence of adverse maternal or foetal effect.

Results: There was pain reduction at 1 and 2 hours in both groups (p<0.001). However, it was more significant in the acetaminophen group, especially at 1 hour. Duration of labour was shortened in both the groups, without any maternal and foetal adverse effects.

Conclusion: Intravenous acetaminophen is an efficacious non-opioid drug for relieving labour pain without any significant maternal and foetal adverse effects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028474PMC
http://dx.doi.org/10.7860/JCDR/2016/19786.8375DOI Listing

Publication Analysis

Top Keywords

efficacy intravenous
8
intravenous infusion
8
acetaminophen intrapartum
8
intrapartum analgesia
8
group n=100
8
acetaminophen
4
infusion acetaminophen
4
analgesia
4
analgesia introduction
4
introduction intensity
4

Similar Publications

ROS-responsive poly(β-amino ester) nanoparticles enable targeted delivery of mRNA vaccine to splenic antigen-presenting cells.

Chem Commun (Camb)

January 2025

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, P. R. China.

Intravenous mRNA vaccines show promise for stimulating immune cells but face challenges in targeting APCs due to high liver accumulation. To address this, we developed ROS-responsive PBAE nanoparticles, 93-TKA10-19, designed to target splenic APCs, enhance mRNA expression, and induce a Th1-skewed immune response, advancing mRNA vaccine efficacy.

View Article and Find Full Text PDF

Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review.

J Crohns Colitis

January 2025

Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.

Background: One third of patients with acute severe ulcerative colitis (ASUC) are steroid-refractory. Cyclosporine and infliximab are currently the mainstays of salvage therapy. Janus kinase inhibitors (JAKi) could play a role in the treatment of ASUC.

View Article and Find Full Text PDF

Background: Pulmonary embolism (PE) is a frequent cause of death. Acute PE may be treated either with full anticoagulation (AC) alone or thrombolytic therapy with systemic tissue-- type-plasminogen-activator (tPA) based on risk assessment. Currently, AC is the standard of care for most patients with intermediate-high-risk PE, with low-dose tPA emerging as an effective alternative.

View Article and Find Full Text PDF

Background: Since there is currently no cure for amyotrophic lateral sclerosis (ALS), it is essential to search for diagnostic biomarkers and novel treatments to reduce the severity of this disease. One of these treatment approaches is stem cell transplantation.

Objective: This study aims to evaluate the safety and efficacy of repeated transplantation of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in patients with ALS by analyzing clinical and molecular data.

View Article and Find Full Text PDF

Objective: The arginase inhibitor INCB001158 was evaluated for safety (primary endpoint) in locally advanced or metastatic solid tumours; pharmacokinetics, pharmacodynamics and efficacy were also assessed.

Methods And Analysis: In this non-randomised, open-label, three-part phase 1 study, INCB001158 was orally administered two times per day as monotherapy or in combination with intravenous pembrolizumab 200 mg every 3 weeks. Dose expansion was conducted in tumour-type cohorts (with or without prior anti-PD-1/PD-L1 (programmed death protein 1/programmed death ligand 1) therapy).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!